[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_100":101},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","fb3qvbi4ebk24l5mcxl8hf8ix","revision",2,"title","Bluejay Diagnostics 完成制造相关合同义务","originalTitle","Bluejay Diagnostics, Inc. (0001704287) (Filer)","summary","Bluejay Diagnostics 完成部分制造相关合同义务。公司于10月13日发布声明，未提及具体产品或技术细节。该信息未纳入任何证券法规文件的正式披露。","reason","source",{"_11":90,"_91":92,"_93":94,"_95":57,"_96":97,"_98":99},"links",{"_87":88,"_63":89},"publishedAt","2026-10-13T13:09:40.000Z","discoveredAt","2026-10-13T13:42:10.029Z","timelineAt","category","ai-products","tags",[81,82,83,84,85,86],"stockSymbols",[80],"score",22,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fM9HrzjZaUDk",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","a4ee575e-aa65-483d-a1cb-ba7bc536b952","Bluejay Diagnostics 完成制造合同义务",{"_72":73,"_15":74},"zh","

UNITED\nSTATES

SECURITIES\nAND EXCHANGE COMMISSION

Washington,\nD.C. 20549

FORM\n8-K

CURRENT\nREPORT

Pursuant\nto Section 13 or 15(d) of the

Securities\nExchange Act of 1934

Date\nof Report (Date of earliest event reported): October 13, 2026

$\"\"$

BLUEJAY\nDIAGNOSTICS, INC.

(Exact\nName of Registrant as Specified in its Charter)

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n


delaware	001-41031	47-3552922
(State or Other Jurisdiction of \nIncorporation or Organization)	(Commission File No.)	(I.R.S. Employer \nIdentification No.)

360\nMassachusetts Avenue, Suite 203

Acton, MA 01720

(Address\nof principal executive offices and zip code)

(844) 327-7078

(Registrant’s\ntelephone number, including area code)

(Former\nname or former address, if changed from last report)

Check\nthe appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under\nany of the following provisions (see General Instruction A.2. below):

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

☐	Written communications\n pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting\n material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement\n communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement\n communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))

Indicate\nby check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405\nof this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging\ngrowth company ☒

If\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities\nregistered pursuant to Section 12(b) of the Act:

\n \n \n \n \n \n \n \n \n \n \n \n \n

Title\n of each class		Trading\n Symbol (s)		Name\n of each exchange on which registered
Common\n Stock, par value $0.0001 per share		BJDX		The Nasdaq Stock\n Market LLC

Item\n7.01 Regulation FD Disclosure.

On\nOctober 13, 2026, Bluejay Diagnostics, Inc. issued a press release regarding, among other things, the completion of certain manufacturing-related\ncontractual obligations.

The\ninformation contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed”\nfor the purpose of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any filing under the\nExchange Act or the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference.

Item\n9.01. Financial Statements and Exhibits.

(d)\nExhibits

\n \n \n \n \n \n \n \n \n

99.1		Press Release, dated October 13, 2026.
104		Cover Page Interactive Data\n File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned, hereunto duly authorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

	Bluejay Diagnostics, Inc.

	By:	/s/\n Neil Dey
		Neil Dey
		President\n and Chief Executive Officer

Date:\nOctober 13, 2026

","zhKind","complete","BJDX","公司与财报","财报","IPO","退市","停复牌","其他","aihot","/items/fb3qvbi4ebk24l5mcxl8hf8ix","https://www.sec.gov/Archives/edgar/data/1704287/000121390026108779/0001213900-26-108779-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792108800&sig=e4adf00b596060d2","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792108800&sig=208b33ec2756b0ea 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792108800&sig=786fcd6a5ff8379c 96w","changelogVersion","2026-10-01T08:00"]